The oncology team from Fudan University further classified HER2-positive breast cancer into four subtypes through multi-omics analysis, involving a classical HER2 subtype, immunomodulatory subtype, luminal-like subtype, and basal/mesenchymal-like subtype [9]. Here, ERBB2 is linked to breast carcinoma.